BRD2 and fungal keratitis: Evidence also suggests that NAT achieves significant, long-lasting antifungal effects by binding to the necrotic substances in lesions.23 Despite all that, NAT, owing to its poor penetration ability, demonstrates relatively low bioavailability and an inferior efficacy profile in treating a deep corneal infection.24 Fungal keratitis-induced corneal damage entails a risk of immunomodulatory disorders and diminished antimicrobial activity.